# KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial

> **NCT05882305** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Kousai Bio Co., Ltd.**

## Conditions studied

- EBV-associated Lymphomas

## Interventions

- **BIOLOGICAL:** Autologous monocyte-derived DCs pulsed withEBV-associated antigen

## Key facts

- **NCT ID:** NCT05882305
- **Lead sponsor:** Kousai Bio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06-10
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No Participants Enrolled
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05882305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05882305, "KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05882305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*